The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,035,951 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Safebeat RX Inc. in San Francisco, CA. The goal of this project is to develop a novel, automated mobile heart rhythm analysis technology that will allow patients with atrial fibrillation (AF) to safely start antiarrhythmic medications at home, thereby improving cardiovascular outcomes and quality of life. This 2-year project, with an end date of June 30, 2026, aims to address the current restriction on access to many antiarrhythmic drugs due to the requirement for a 3-day hospitalization to initiate oral medication. The proposed technology would enable patients to start these potentially life-saving drugs safely at home, reducing the burden on the healthcare system.
Generated 3/4/25, 8:21 AM